Therefore the clinical PFD dose could be sufficient to enhance PARK2 protein levels, which may exert beneficial effects via mitophagy activation and maintaining mitochondrial integrity during IPF pathogenesis. This evidence concerns the gene PRKN and idiopathic pulmonary fibrosis.